Primary sclerosing cholangitis: Epidemiology, natural history, and prognosis

Cynthia Levy, Keith D. Lindor

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Primary sclerosing cholangitis is a progressive disease associated with significant morbidity and mortality that continues to draw attention from investigators worldwide. Epidemiologic studies indicate that its annual incidence remains stable, although more asymptomatic cases are being diagnosed. Nevertheless, even asymptomatic cases can progress to end-stage liver disease, albeit at a highly variable rate. Moreover, patients are predisposed to several malignancies, especially cholangiocarcinoma, which contributes to their decreased survival. On the other hand, a subgroup of patients with the so-called small-duct variant may have a better prognosis, and those with overlap syndromes with autoimmune hepatitis may respond well to immunosuppressants. Otherwise, efficient treatment is not available for patients with primary sclerosing cholangitis. Thus, even though it occurs rarely, this disease is commonly an indication for liver transplantation. Fortunately, transplantation outcomes are excellent, with overall 5-year survival rates of approximately 80%.

Original languageEnglish
Pages (from-to)22-30
Number of pages9
JournalSeminars in Liver Disease
Volume26
Issue number1
StatePublished - Feb 1 2006
Externally publishedYes

Fingerprint

Sclerosing Cholangitis
Natural History
Epidemiology
Autoimmune Hepatitis
End Stage Liver Disease
Cholangiocarcinoma
Immunosuppressive Agents
Liver Transplantation
Epidemiologic Studies
Survival Rate
Transplantation
Research Personnel
Morbidity
Survival
Mortality
Incidence
Neoplasms
Therapeutics

Keywords

  • Epidemiology
  • Liver transplantation
  • Natural history
  • Primary sclerosing cholangitis

ASJC Scopus subject areas

  • Hepatology

Cite this

Primary sclerosing cholangitis : Epidemiology, natural history, and prognosis. / Levy, Cynthia; Lindor, Keith D.

In: Seminars in Liver Disease, Vol. 26, No. 1, 01.02.2006, p. 22-30.

Research output: Contribution to journalArticle

@article{0b49b0b8caac4b9b8b31d2f6df142b53,
title = "Primary sclerosing cholangitis: Epidemiology, natural history, and prognosis",
abstract = "Primary sclerosing cholangitis is a progressive disease associated with significant morbidity and mortality that continues to draw attention from investigators worldwide. Epidemiologic studies indicate that its annual incidence remains stable, although more asymptomatic cases are being diagnosed. Nevertheless, even asymptomatic cases can progress to end-stage liver disease, albeit at a highly variable rate. Moreover, patients are predisposed to several malignancies, especially cholangiocarcinoma, which contributes to their decreased survival. On the other hand, a subgroup of patients with the so-called small-duct variant may have a better prognosis, and those with overlap syndromes with autoimmune hepatitis may respond well to immunosuppressants. Otherwise, efficient treatment is not available for patients with primary sclerosing cholangitis. Thus, even though it occurs rarely, this disease is commonly an indication for liver transplantation. Fortunately, transplantation outcomes are excellent, with overall 5-year survival rates of approximately 80{\%}.",
keywords = "Epidemiology, Liver transplantation, Natural history, Primary sclerosing cholangitis",
author = "Cynthia Levy and Lindor, {Keith D.}",
year = "2006",
month = "2",
day = "1",
language = "English",
volume = "26",
pages = "22--30",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "1",

}

TY - JOUR

T1 - Primary sclerosing cholangitis

T2 - Epidemiology, natural history, and prognosis

AU - Levy, Cynthia

AU - Lindor, Keith D.

PY - 2006/2/1

Y1 - 2006/2/1

N2 - Primary sclerosing cholangitis is a progressive disease associated with significant morbidity and mortality that continues to draw attention from investigators worldwide. Epidemiologic studies indicate that its annual incidence remains stable, although more asymptomatic cases are being diagnosed. Nevertheless, even asymptomatic cases can progress to end-stage liver disease, albeit at a highly variable rate. Moreover, patients are predisposed to several malignancies, especially cholangiocarcinoma, which contributes to their decreased survival. On the other hand, a subgroup of patients with the so-called small-duct variant may have a better prognosis, and those with overlap syndromes with autoimmune hepatitis may respond well to immunosuppressants. Otherwise, efficient treatment is not available for patients with primary sclerosing cholangitis. Thus, even though it occurs rarely, this disease is commonly an indication for liver transplantation. Fortunately, transplantation outcomes are excellent, with overall 5-year survival rates of approximately 80%.

AB - Primary sclerosing cholangitis is a progressive disease associated with significant morbidity and mortality that continues to draw attention from investigators worldwide. Epidemiologic studies indicate that its annual incidence remains stable, although more asymptomatic cases are being diagnosed. Nevertheless, even asymptomatic cases can progress to end-stage liver disease, albeit at a highly variable rate. Moreover, patients are predisposed to several malignancies, especially cholangiocarcinoma, which contributes to their decreased survival. On the other hand, a subgroup of patients with the so-called small-duct variant may have a better prognosis, and those with overlap syndromes with autoimmune hepatitis may respond well to immunosuppressants. Otherwise, efficient treatment is not available for patients with primary sclerosing cholangitis. Thus, even though it occurs rarely, this disease is commonly an indication for liver transplantation. Fortunately, transplantation outcomes are excellent, with overall 5-year survival rates of approximately 80%.

KW - Epidemiology

KW - Liver transplantation

KW - Natural history

KW - Primary sclerosing cholangitis

UR - http://www.scopus.com/inward/record.url?scp=33644630329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644630329&partnerID=8YFLogxK

M3 - Article

C2 - 16496230

AN - SCOPUS:33644630329

VL - 26

SP - 22

EP - 30

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 1

ER -